Platinum OpinionThe 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor–based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care
References (15)
- et al.
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Lancet (Lond, Engl)
(2019) - et al.
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Lancet Oncol
(2020) - et al.
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
ESMO Open
(2020) - et al.
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
Ann Oncol
(2020) - et al.
Updated European Association of Urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma
Eur Urol
(2021) - et al.
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Lancet Oncol
(2015) - et al.
Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma
N Engl J Med
(2021)
There are more references available in the full text version of this article.
Cited by (0)
© 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.